UBS Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-9
| Closed | -$45 | – | 10446 |
|
|
2024
Q1 | $45 | Sell |
9
-359
| -98% | -$2.23K | ﹤0.01% | 8942 |
|
|
2023
Q4 | $2.48K | Buy |
368
+366
| +18,300% | +$3.22K | ﹤0.01% | 8104 |
|
|
2023
Q3 | $18 | Buy |
+2
| New | +$40 | ﹤0.01% | 9143 |
|
|
2023
Q2 | – | Sell |
-453
| Closed | -$14K | – | 8779 |
|
|
2023
Q1 | $12.2K | Sell |
453
-75
| -14% | -$3.49K | ﹤0.01% | 7454 |
|
|
2022
Q4 | $18.7K | Buy |
528
+365
| +224% | +$43.8K | ﹤0.01% | 7721 |
|
|
2022
Q3 | $37K | Sell |
163
-57
| -26% | -$14K | ﹤0.01% | 6647 |
|
|
2022
Q2 | $42K | Sell |
220
-220
| -50% | -$44.3K | ﹤0.01% | 6069 |
|
|
2022
Q1 | $110K | Buy |
440
+4
| +0.9% | +$632 | ﹤0.01% | 5848 |
|
|
2021
Q4 | $68K | Buy |
436
+310
| +246% | +$59.9K | ﹤0.01% | 6654 |
|
|
2021
Q3 | $25K | Buy |
126
+48
| +62% | +$11.4K | ﹤0.01% | 6935 |
|
|
2021
Q2 | $20K | Sell |
78
-3
| -4% | -$749 | ﹤0.01% | 7351 |
|
|
2021
Q1 | $22K | Sell |
81
-2,855
| -97% | -$900K | ﹤0.01% | 7307 |
|
|
2020
Q4 | $1.08M | Buy |
2,936
+280
| +11% | +$80.3K | ﹤0.01% | 3952 |
|
|
2020
Q3 | $648K | Sell |
2,656
-337
| -11% | -$105K | ﹤0.01% | 3971 |
|
|
2020
Q2 | $862K | Buy |
2,993
+710
| +31% | +$209K | ﹤0.01% | 3641 |
|
|
2020
Q1 | $466K | Buy |
2,283
+1,372
| +151% | +$437K | ﹤0.01% | 4029 |
|
|
2019
Q4 | $407K | Buy |
911
+341
| +60% | +$121K | ﹤0.01% | 5024 |
|
|
2019
Q3 | $175K | Buy |
570
+553
| +3,253% | +$180K | ﹤0.01% | 5346 |
|
|
2019
Q2 | $5K | Hold |
17
| – | – | ﹤0.01% | 7402 |
|
|
2019
Q1 | $7K | Sell |
17
-55
| -76% | -$22.1K | ﹤0.01% | 7031 |
|
|
2018
Q4 | $22K | Buy |
72
+41
| +132% | +$13.2K | ﹤0.01% | 6714 |
|
|
2018
Q3 | $11K | Buy |
31
+14
| +82% | +$4.79K | ﹤0.01% | 7128 |
|
|
2018
Q2 | $6K | Sell |
17
-36
| -68% | -$12.8K | ﹤0.01% | 7427 |
|
|
2018
Q1 | $16K | Buy |
53
+2
| +4% | +$591 | ﹤0.01% | 6579 |
|
|
2017
Q4 | $21K | Buy |
51
+50
| +5,000% | +$17.9K | ﹤0.01% | 6528 |
|
|
2017
Q3 | $0 | Sell |
1
-1
| -50% | -$272 | ﹤0.01% | 8081 |
|
|
2017
Q2 | $0 | Sell |
2
-51
| -96% | -$11.6K | ﹤0.01% | 8071 |
|
|
2017
Q1 | $18K | Buy |
53
+25
| +89% | +$8.61K | ﹤0.01% | 6224 |
|
|
2016
Q4 | $10K | Buy |
28
+4
| +17% | +$1.47K | ﹤0.01% | 6932 |
|
|
2016
Q3 | $10K | Buy |
+24
| New | +$12.2K | ﹤0.01% | 6798 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 8035 |
|
|
2016
Q1 | – | Sell |
-3
| Closed | -$1.49K | – | 8322 |
|
|
2015
Q4 | $2K | Buy |
+3
| New | +$1.7K | ﹤0.01% | 8041 |
|
|
2015
Q3 | – | Sell |
-33
| Closed | -$17.5K | – | 8707 |
|
|
2015
Q2 | $18K | Buy |
33
+31
| +1,550% | +$85.8K | ﹤0.01% | 6985 |
|
|
2015
Q1 | $17K | Hold |
2
| – | – | ﹤0.01% | 7161 |
|
|
2014
Q4 | $18K | Buy |
+2
| New | +$11.6K | ﹤0.01% | 7809 |
|
Other funds holding EIGR
UBS Group's EIGR Position: Q2 2024 in Review
UBS Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 9 shares — an estimated $45 sold.
UBS Group first reported a position in EIGR in Q4 2014 and held it in 34 quarters. The position peaked at $1.08M in Q4 2020. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.
- UBS Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- UBS Group sold 9 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $45.
- UBS Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 34 quarters.
- UBS Group's Eiger BioPharmaceuticals, Inc. position peaked at $1.08M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.